JR Larsen et al.  JAMA Psychiatry 74 (7), 719-728. 01 Jul 2017 Jul.

Obesity is one of the most significant side-effects of antipsychotic medication.  Current management of this problem includes weight monitoring, dietary advice and the use of glucose-lowering medicines such as metformin.  Liraglutide is a glucagon-like peptide 1 receptor agonist and a relatively new medication for diabetes.  This is one of the first studies to investigate its value in preventing diabetes in people receiving antipsychotic medication.  This Danish study showed that Liraglutide could improve body mass index, glucose tolerance, waist circumference, blood pressure and visceral fat, when compared with placebo. As with metformin, there were some gastrointestinal side-effects, but otherwise, Liraglutide was well tolerated.

https://www.ncbi.nlm.nih.gov/labs/articles/28601891/